From Multi-Omics Approaches to Precision Medicine in Amyotrophic Lateral Sclerosis

• Main Authors: Giovanna Morello, Salvatore Salomone, Velia D’Agata, Francesca Luisa Conforti, Sebastiano Cavallaro
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2020-10-01
• Series: Frontiers in Neuroscience
• Subjects: amyotrophic lateral sclerosis; ALS-FTD; personalized medicine; molecular taxonomy; multi-omics; systems biology
• Online Access: https://www.frontiersin.org/articles/10.3389/fnins.2020.577755/full

Amyotrophic lateral sclerosis (ALS) is a devastating and fatal neurodegenerative disorder, caused by the degeneration of upper and lower motor neurons for which there is no truly effective cure. The lack of successful treatments can be well explained by the complex and heterogeneous nature of ALS, with patients displaying widely distinct clinical features and progression patterns, and distinct molecular mechanisms underlying the phenotypic heterogeneity. Thus, stratifying ALS patients into consistent and clinically relevant subgroups can be of great value for the development of new precision diagnostics and targeted therapeutics for ALS patients. In the last years, the use and integration of high-throughput “omics” approaches have dramatically changed our thinking about ALS, improving our understanding of the complex molecular architecture of ALS, distinguishing distinct patient subtypes and providing a rational foundation for the discovery of biomarkers and new individualized treatments. In this review, we discuss the most significant contributions of omics technologies in unraveling the biological heterogeneity of ALS, highlighting how these approaches are revealing diagnostic, prognostic and therapeutic targets for future personalized interventions.